2010
DOI: 10.1001/jama.2010.1676
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic Interventions for Systemic Vasculitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2011
2011
2013
2013

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…Mycophenolate mofetil is an immunosuppressive drug mainly used in the prevention of allograft rejection in renal, cardiac or liver transplantation and in immune-mediated diseases, such as systemic lupus erythematosus, with or without renal involvement (Bomback & Appel, 2010;Mok, 2007), systemic vasculitis (Hoffman, 2010), autoimmune rheumatic diseases (Iaccarino et al, 2007) and myasthenia gravis (Hehir et al, 2010). Mycophenolate mofetil is a prodrug of mycophenolic acid that was developed to enhance its bioavailability.…”
Section: Introductionmentioning
confidence: 99%
“…Mycophenolate mofetil is an immunosuppressive drug mainly used in the prevention of allograft rejection in renal, cardiac or liver transplantation and in immune-mediated diseases, such as systemic lupus erythematosus, with or without renal involvement (Bomback & Appel, 2010;Mok, 2007), systemic vasculitis (Hoffman, 2010), autoimmune rheumatic diseases (Iaccarino et al, 2007) and myasthenia gravis (Hehir et al, 2010). Mycophenolate mofetil is a prodrug of mycophenolic acid that was developed to enhance its bioavailability.…”
Section: Introductionmentioning
confidence: 99%